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Age-related macula degeneration (AMD) can be thought
of as a sub-type of retinal degeneration. Although the primary
site of injury in AMD is unknown, it is ultimately the loss of
photoreceptor function that leads to visual loss. As described
in the accompanying article [1], one approach to gaining a
better understanding of the disease process is to directly study
the genetics of AMD. A second and complementary approach
is to take advantage of the increasing body of knowledge about
the genetics and molecular basis of other forms of photore-
ceptor degeneration (see RetNet). Although the specific genes
involved, in many cases, may turn out to be different, knowl-
edge about the genetics and biology of photoreceptor cell death
in general is likely to provide insights that will be helpful in
understanding the pathogenesis of AMD. This latter approach
was the unifying theme of the session entitled “What can we
learn about AMD from other retinal diseases?”
As noted in the accompanying article [1], some of the
difficulties in studying AMD are its late onset (which limits
the availability of large pedigrees), complex genetics, and prob-
able strong environmental component. In such situations, it
can be useful to study related clinical diseases that demon-
strate earlier clinical presentation and simpler Mendelian in-
heritance patterns. As one example of the successful use of
this approach, analysis of a rare juvenile form of glaucoma
led to the identification and cloning of a gene that, at least in
some populations, is responsible for 2-4% of the far more com-
mon adult onset primary open angle glaucoma [2]. Based on a
similar rationale, a number of groups have been studying early
onset forms of macular degeneration that show Mendelian
inheritance patterns, such as Stargardt disease and Best dis-
ease. Several talks in the session were devoted to ABCR/RIM,
the gene that is responsible for most, and perhaps all, cases of
Stargardt disease.
Jeremy Nathans reviewed the positional cloning of the
ABCR/RIM [3]. He also pointed out that ABCR/RIM was in-
dependently cloned using a protein purification and sequenc-
ing approach [4]. ABCR/RIM encodes a 220 kd retina-spe-
cific member of the ABC transporter superfamily, which in-
cludes such proteins as CFTR, P-glycoprotein and TAP1 and
TAP2. Immunocytochemical studies have demonstrated that
it is localized to disc membranes within rod outer segments
[5]. This finding of rod-specific expression was somewhat
surprising in that, based on the clinical characteristics of
Stargardt disease, many investigators suspected that the pri-
mary gene product would be expressed in RPE cells and/or
perhaps cones. Furthermore, the absence of ABCR/RIM in
cones suggests either that cones express a different transporter
that functions analogously, or that the continuity between cone
outer segment discs and the plasma membrane facilitates trans-
port so that an ABCR/RIM homologue is not required.
A major unresolved question is what is the function of
ABCR/RIM; more specifically, what does it transport? If, like
rhodopsin, some fraction of the ABCR/RIM protein resides in
the rod outer segment plasma membrane, then ABCR/RIM
may transport a small molecule or ion into or out of the outer
segment. An alternative and intriguing possibility is that
ABCR/RIM facilitates the movement of a small molecule
within the rod outer segment, specifically between the lumi-
nal and cytosolic faces of the disc membrane. Such a function
could be analogous to the lipid “flippase” activity seen in the
mdr class of ABC transporters. In this regard, it is interesting
that a major constituent of human RPE lipofuscin, which is
associated with normal aging, has been identified as N-retinyl-
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Over the last 10 years there has been an explosion of new information about the genetics of retinal disease. Over 104
genetic loci have been mapped and more than 45 disease causing genes have been identified (see RetNet). The biology of
some of these genes is beginning to be understood and animal models that express some of these mutated human genes
have been developed. It is likely that the increasing knowledge derived from these studies will have implications for
understanding the genetics and pathogenesis of age related macular degeneration (AMD). Selected aspects of the genetics
and biology of photoreceptor degeneration are presented, including the role of ABCR in Stargardt disease and its possible
relationship to AMD, the role of rom-1, rds-peripherin, and CRX in various forms of photoreceptor degeneration, and the
development and initial characterization of mice carrying targeted deletions of the OAT, TIMP-3, and RPE65 genes. The
relevance and limitations of these studies for helping to understand AMD are discussed.
N-retinylethanolamine. N-retinyl-N-retinylethanolamine has
been proposed to form in the disc membrane by reaction of
retinal and phosphatidylethanolamine. If it or a related deriva-
tive does indeed constitute the RPE lipofuscin that accumu-
lates in Stargardt disease, then this model suggests that it may
have formed as a result of defective ABCR-mediated trans-
port of retinoids within the rod outer segment.
In an effort to experimentally identify ABCR/RIM’s trans-
port substrate, Dr. Nathans described his lab’s ongoing efforts
at development of a reconsituted transport assay system. The
systen is based on the finding that some ABC transporters show
an increase in ATPase activity upon addition of their substrates.
Using immunoaffinity purified ABCR/RIM from bovine rod
outer segments, various compounds are being tested for their
ability to increase, or decrease, baseline ATPase activity. Pre-
liminary studies demonstrate that retinal can significantly
stimulate ABCR ATPase activity, but vectoral transport has
not yet been demonstrated [6].
Michael Dean discussed the genetics of ABCR/RIM [3].
Classical Stargardt disease, which maps to chromosome lp22,
is inherited in an autosomal recessive manner. Over 150 unre-
lated Stargardt patients have been analyzed and over 80 dif-
ferent ABCR mutations have been identified. Many of the
mutations are missense alterations and all compound heterozy-
gotes identified to date contain at least one missense or in
frame deletion allele. This suggests that expression of an ab-
errant ABCR protein is required to produce a Stargardt phe-
notype. Mutations in ABCR/RIM have also been identified
with other retinal phenotypes. For example, patients homozy-
gous for a frame-shift mutation in the N-terminal region of
ABCR present with retinitis pigmentosa (RP19) [7]. Additional
RP and cone-rod dystrophy families with ABCR mutations
have also been described [8,9].
The similarity between STGD and some forms of age-
related macular degeneration (AMD), and the presence of
AMD in some obligate carriers for ABCR mutations, led to
the examination of a potential role of ABCR in AMD [10]. A
cohort of 167 AMD patients was screened for alterations in
the ABCR gene. A total of 19 alterations affecting the coding
potential or processing of the gene were identified. The pres-
ence of each alteration was also examined in at least 220 popu-
lation controls. Three common polymorphisms were found
that were nearly equally distributed between patients and con-
trols. However, 12 rare variants were found exclusively or
nearly exclusively in AMD subjects. These AMD-associated
variants included frame-shift and splice site mutations as well
as 6 alleles also found in STGD patients. No single variant is
significantly associated with AMD, if a conservative
Bonferroni correction is applied. However, tests that combine
alleles (i.e. CLUMP) demonstrate that ABCR variants are
disproportionally found in our AMD subjects. While 40/167
of the AMD subjects had neo-vascularization, only 1/26 pa-
tients with ABCR alterations had “wet” AMD. Based on these
results, it was hypothesized that some ABCR alleles can pre-
dispose an individual to AMD, particularly the “dry” form.
Ongoing studies are analyzing the ABCR gene in other groups
of patients with AMD, including patients from the Age-Re-
lated Eye Disease Study (AREDS).
It should be noted that the relationship between sequence
changes in ABCR/RIM and AMD is controversal [11,12].
Edwin M. Stone presented some of the arguments that sug-
gest that at least some of the reported AMD “mutations” in
ABCR/RIM are more likely to be polymorphisms rather than
disease causing mutations [12]. He first discussed the differ-
ences between “sequence variant,” “mutation,” and “disease-
causing mutation,” and the difficulties in functionally distin-
guishing between these terms. A base change identified in a
particular gene, even if it co-segregates with a disease, is not
necessarily the cause of that disease. Assigning causality can
be complicated by incomplete penetrance, as well as variable
environmental effects and modifier genes. As one studies more
prevalent diseases (which tend to be the ones with greater
public health importance), such as AMD, and genes that are
highly polymorphic, such as ABCR, establishing causality
becomes even more difficult.
The choice of an appropriate control population can also
be very important. The outbred human population is very di-
verse and there have now been identified a number of examples
of subpopulations of individuals that harbor common poly-
morphisms that are rare in other seemingly similar popula-
tions. Subtle differences in control and experimental popula-
tions can lead to unappreciated differences in allele frequen-
cies and thereby result in the mistaken identification of a poly-
morphism as a disease-causing mutation.
With these issues in mind, Dr. Stone and colleagues ana-
lyzed their available patient populations for base changes in
their ABCR genes. One hundred eighty two individuals with
AMD, 215 Stargardt families, and 96 control “normal” pa-
tients were studied. The AMD patients were from the Univer-
sity of Iowa retina clinic, and the majority of them had evi-
dence of neovascular disease. The entire ABCR gene was
screened for both the disease and control populations.
Thirteen hundred twenty one sequence variants were iden-
tified, of which 147 were distinct. Using the Bonferroni cor-
rection, none of the identified sequence changes were calcu-
lated to be significantly more common in the AMD popula-
tion than in the control population.
In contrast to the situation with AMD, in confirmation of
the prior work indicating that ABCR mutations are respon-
sible for Stargardt disease, a number of sequence changes were
found to be present statistically significantly more commonly
in the Stargardt population than in the control population. It
should also be pointed out that for the Stargardt patients, it
was estimated that as many as 50% of the disease causing
mutations were not identified.
Following Dr. Stone’s presentation, there was lively de-
bate about the various issues raised. The fact that the AMD
patients studied by Dr. Dean and colleagues had primarily non-
neovascular AMD, whereas those studied by Dr. Stone and
colleagues had primarily neovascular AMD, was discussed as
one possible partial explanation for the differences in results
between the groups. An important point that was clear from
the discussion is that additional studies will be needed to re-
solve the controversies surrounding the role of ABCR muta-
tions in AMD.
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Bob Molday briefly commented upon the cloning and
characterization of ABCR/RIM and its involvement in
Stargardt disease [4,13], but concentrated his presentation of
the biochemical interaction of peripherin/rds and rom-1. A large
number of mutations in peripherin/rds, a membrane protein
required for rod and cone outer segment morphogenesis, have
been associated with autosomal dominant RP and a variety of
pattern (e.g. butterfly-shaped pigment dystrophy, Bull’s Eye
and adult vitelliform macular dystrophy, cone-rod pattern dys-
trophy, and fundus flavimaculatus). In addition, an L185P mu-
tation in peripherin/rds, together with a null mutation in its
homologous subunit rom-1, have been identified in a novel
digenic form of autosomal dominant RP [14].
In an effort to understand the molecular basis for retinal
degenerative diseases linked to mutations in peripherin/rds and
rom-1, a heterologous (COS-1) cell system for expressing wild-
type and mutant peripherin/rds singly or together with rom-1
was developed [15-18]. In this system mmunofluorescence
microscopy and western blotting is used to monitor protein
expression. The protein complex is then extracted from the
membranes with a mild detergent and subunit assembly is
analyzed by immunoprecipitation and velocity sedimentation.
Using this experimental approach, it has been shown that het-
erologously expressed wild-type peripherin/rds and rom-1 co-
assemble into a heterotetramer that has similar structural prop-
erties to the peripherin/rds-rom-1 complex derived from na-
tive photoreceptor membranes. In the absence of rom-1, het-
erologously expressed peripherin/rds self-assembles into a
homotetramer. In contrast, when the C214S peripherin/rds
mutant implicated in monogenic autosomal dominant RP is
expressed in COS-1 cells, the protein is misfolded and inca-
pable of interacting with rom-1 or with itself. One hypothesis
to account for the observed photoreceptor degeneration is that
insufficient amounts of normal peripherin/rds tetramers and/
or a negative effect of the misfolded C214S mutant inhibits
normal outer segment morphogenesis in these patients.
The expression system has also been used to analyze the
digenic form of autosomal dominant RP linked to an L185P
mutation in peripherin/rds and a frameshift mutation in rom-1
that results in a null allele. The expression studies indicate
that defective subunit assembly is responsible for this novel
form of autosomal dominant RP. In particular, L185P mutant
peripherin/rds forms a native-like complex with rom-1, but it
is unable to self-assemble into a homotetramer in the absence
of rom-1. On the basis of these studies, a subunit assembly
model has been developed that emphasizes the dominant role
of peripherin/rds-containing oligomers in outer segment disk
formation and provides a molecular rationale for phenotypes
of individuals who inherit one or both digenic mutations. One
prediction of this model is that in the absence of rom-1,
peripherin/rds homotetramers can effectively replace
peripherin/rds-rom-1 heterotetramers and promote outer seg-
ment formation. This prediction has now been tested and con-
firmed in ROM-1 knockout mice produced by G. Clark and
Rod McInnes (University of Toronto).
Donald J. Zack summarized the cloning and character-
ization of the Cone Rod Homeobox (CRX) transcription fac-
tor and its emerging role in retinal disease [19-21]. CRX is a
member of the Otx/Otd subfamily of paired-like homeodomain
transcription factors. As its name implies, it is specifically
expressed in rod and cone cells. (It is also expressed in
pinealocytes, which in some species are light sensitive [22].)
Crx was cloned by three different approaches: based on it’s
ability to bind to the rhodopsin promoter [19], based on its
sequence similarity to Chx10 [20], and based on its homology
to “typical” homeodomain containing genes [21]. Crx protein
binds to the promoters of a number of photoreceptor-specific
genes. In a cell culture transient transfection assay, Crx
transactivates the expression of a several photoreceptor-spe-
cific genes, including rhodopsin, IRBP, b-phosphodiesterse,
and arrestin. In addition, it acts synergistically with the neural
retina leucine zipper (Nrl) protein [23] in activating rhodop-
sin expression.
Human chromosomal mapping revealed that CRX is lo-
cated at 19q13.3, which is at or near the site of a previously
mapped cone-rod dystrophy (CORDII). Analysis of the CRX
genes from several hundred patients has revealed that approxi-
mately 5% of CORD patients carry a mutation in one of their
CRX genes. Amongst the mutations that have been identified
are Arg41Trp, Arg41Gln, E80A, Val242Met, and a 4 bp dele-
tion in codons 196/7 [20,24,25]. Some of the mutations are in
the DNA binding homeodomain, whereas others are in the
more C-terminal part of the molecule, possibly in the activa-
tion domain.
CRX mutations have also been identified in a number of
cases of Leber’s Congenital Amaurosis (LCA), a condition in
which children have significant loss of photoreceptor func-
tion at or near the time of birth [26]. Surprisingly, since most
cases of LCA are thought to be recessive, in the cases pub-
lished to date only a single mutated CRX allele was identi-
fied. Furthermore, in each case the mutated allele was not found
in either of the parents. This suggests that the identified muta-
tions arose de novo and that the disease phenotype in these
cases may be inherited in an autosomal dominant manner. This
finding, if confirmed, may have implications for genetic coun-
seling of LCA patients.
To increase the complexity, CRX mutations have also been
reported in patients with retinitis pigmentosa [25]. How dif-
ferent, yet sometimes very similar, mutations in CRX can cause
different clinical phenotypes is unclear, although it is reminis-
cent of the clinical diversity observed with mutations in other
genes such as rds/peripherin and ABCR. Since CRX appears
to regulate the expression of a number of photoreceptor genes,
it is possible that different CRX mutations differentially af-
fect the expression of CRX’s array of target genes and thereby
cause different clinical pictures. Alternatively, or in addition,
modifier genes or environmental factors may influence the
phenotypes associated with CRX mutations. Efforts to resolve
these issues utilizing in vitro assays of the function of the vari-
ous mutant CRX alleles are underway.
At least one case of congenital blindness caused by auto-
somal recessive CRX mutations has also been identified.
Anand Swaroop reported on a family with LCA in which the
affected individual is homozygous for a R90W CRX muta-
tion [27]. The parents of the LCA patient were heterozygous
for the R90W mutation and, although clinically asymptom-
atic, revealed a subtle abnormality of cone function upon oph-
thalmic examination and electroretinography. In addition, the
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CRX gene was analyzed in 30 patients with AMD, but no mu-
tations were identified.  In a related set of studies, which were
not reported at the meeting, autosomal dominant retinitis
pigmentosa phenotype appears to be associated with a muta-
tion in the NRL gene [28]. This is particularly interesting from
a mechanistic point of view because, as noted above, NRL
can act synergistically with CRX in regulating photoreceptor
gene expression.
The CRX studies demonstrate that mutations in transcrip-
tion factors can, at least in some cases, cause photoreceptor
cell loss with a clinical phenotype that predominantly involves
the macular region. This raises the possibility that sequence
variations in CRX and/or other photoreceptor transcription
factors could be risk factors for some forms of AMD.
The diseases discussed so far are caused by genes that are
expressed preferentially, or exclusively, in photoreceptor cells.
However, genes that are expressed preferentially in RPE cells,
as well as ubiquitously expressed genes (see gyrate atrophy
below), can also cause specific photoreceptor cell loss. T.
Michael Redmond summarized the cloning [29,30] and cur-
rent knowledge about one such gene, RPE65. RPE65, a pro-
tein preferentially and abundantly expressed in the RPE is es-
sential to the maintenance of normal vision. Mutations in the
human RPE65 gene result in rapidly progressive forms of early-
onset retinal dystrophy called autosomal recessive childhood-
onset severe retinal dystrophy (arCSRD), ranging in age of
onset from more severe forms classified as Leber’s congeni-
tal amaurosis (LCAII; OMIM ) to later onset juvenile retinitis
pigmentosa [31,32]. RPE65 has been localized to human chro-
mosome 1p31 and its mouse homolog (Rpe65) to distal mouse
chromosome 3 [33]. By linkage analysis, certain arCSRDs
were linked to the interval occupied by RPE65 and were shown
to be associated with mutations in RPE65. In addition, candi-
date gene analysis of RPE65 identified different mutations in
patients with Leber’s congenital amaurosis, providing a sec-
ond locus for this heterogeneous disorder. Common features
of these patients include loss of vision from birth or early child-
hood, associated with complete night-blindness, extinguished
rod electroretinography, and severely compromised cone re-
sponses. These symptoms are suggestive of a crucial role for
RPE65 in retinal function.
Though its function is not certain, a role in vitamin A me-
tabolism is strongly suspected. Evidence for this is provided
by its association with the retinol-binding protein (RBP) and
11-cis-retinol dehydrogenase. RPE65, also known as p63, has
been proposed to be the RPE RBP receptor, though this pro-
tein does not enhance RBP uptake in transfected cells. Asso-
ciation with the 11-cis-retinol dehydrogenase suggests that it
is part of the visual cycle pathway, the process by which the
11-cis-retinal chromophore of visual pigments is photo-isomer-
ized to the all-trans-isomer, and then regenerated in the dark.
11-cis-retinal, the chromophore of all known opsins, verte-
brate and invertebrate, is restricted to the eye. In the verte-
brate eye, the major site of production of 11-cis-retinoids is
the RPE. Though the phenotype of the human RPE65 null
mutation is compatible with severe disruption of the visual
cycle, resulting in absence of 11-cis-retinal and, ultimately,
blindness, a clearer understanding of the biochemical basis
for this phenotype is required.
In view of the potentially important role of RPE65 in the
physiology of vision and, perhaps, the visual cycle, a targeted
disruption of the mouse Rpe65 gene was generated in order to
more directly assess its function [34]. No effects of the knock-
out on viability were noted. In -/- mice, RPE65 mRNA was
not detectable by RT-PCR. No major changes in RPE mor-
phology were noted in 7-week old +/- or -/- animals, nor was
there loss of photoreceptor nuclei. However, subtle changes
were seen by LM in photoreceptor outer segments (OS) of the
-/-, manifesting as lighter staining of OS. By EM, the discs of
the -/- were disorganized and also not as tightly packed as in
the +/+ and +/-. In contrast, the ERGs of -/- mice were se-
verely abnormal compared to +/- and +/+ littermates. The b-
wave response elicited from -/- animals was strongly depressed.
The threshold stimulus intensity required to elicit this response
was much higher than for +/+ or +/-. Furthermore, rhodopsin
difference spectrum analysis of +/+, +/-, and -/- retinas re-
vealed that -/- retinae had no rhodopsin. Western blot analysis
showed that opsin apoprotein was present in -/- retinas, though
levels were decreased compared to +/+ and +/-. The absence
of rhodopsin holoprotein, even though the apoprotein is
present, indicates severe disruption of 11-cis-retinal supply to
the photoreceptors. This knockout model will provide impor-
tant insights into retinoid metabolism in the outer retina, as
well as pigment synthesis and regeneration. It will also pro-
vide a useful model for LCAII and related arCSRDs and to
study possible therapies for these conditions.
In conclusion, RPE65 null mutations in both human and
mouse show severe changes in visual function. These muta-
tions appear to cause disruption of the vitamin A visual cycle
of the RPE, resulting in interruption of the supply of the 11-
cis-retinal chromophore. The precise nature of this disruption
is under investigation. Though the human and mouse muta-
tions described to date relate to early onset blindness, it is
possible that mutations with less severe effects on RPE65 ex-
pression/function exist and manifest themselves in late onset
disease. In light of this, further analysis of this gene with re-
spect to later onset diseases such as AMD is warranted.
Other retinal diseases caused by genes that are preferen-
tially expressed in the RPE have also been identified. Muta-
tions in the gene for cellular retinaldehyde-binding protein
(CRALBP), which is expressed predominantly in RPE and
Mueller cells, have been identified in patients with in autoso-
mal recessive retinitis pigmentosa [35]. Recently, the gene that
causes Best disease, Bestrophin, was identified and found to
be expressed predominantly in the RPE [36]. Although so far
there is no hint about the function of Bestrophin, given that
Best disease is a macular degeneration and has some similari-
ties to AMD, it seems reasonable to hope that studies on the
function of Bestrophin will provide help in understanding
AMD.
In addition to genes that are preferentially expressed in
photoreceptor and/or RPE cells, widely and even ubiquitously
expressed genes can also cause specific retinal degeneration.
David Valle discussed how general metabolic diseases can
preferentially affect individual tissues or cell types. Gyrate
atrophy of the retina, an autosomal recessive disease, is caused
by deficiency of the widely expressed enzyme ornithine-delta-
aminotransferase (OAT) [37]. Patients demonstrate systemic
© Molecular VisionMolecular Vision 1999; 5:30 <http://www.molvis.org/molvis/v5/p30>
elevation of serum ornithine levels, yet the major phenotype
is a localized chorioretinal degeneration. Missense, nonsense,
and frameshift mutations in the OAT gene have been identi-
fied [38,39]. Promoter mutations have also been suspected,
but not definitively identified.
In order to develop an animal model for gyrate atrophy,
an OAT-deficient mouse was generated by gene targeting.
[40,41]. The mice demonstrate many similarities to the hu-
man disease. Anatomically, there is a slowly progressive reti-
nal degeneration that involves first the RPE (large phagosomes
and crystalloid inclusions), and then the photoreceptors (dis-
organized and short rod outer segments followed by actual
photoreceptor loss). During this period there is also progres-
sive loss of electroretinogram (ERG) amplitude. Once differ-
ence between the mouse model and the human disease is that
in the mice the retinal degeneration is primarily central,
whereas in humans it is more peripheral.
The OAT-deficient mouse is also a valuable resource for
testing potential therapies for gyrate atrophy. Based on the
biochemistry of the disease and limited clinical trials, it has
long been suspected that long term reduction of ornithine with
an arginine-restricted diet slows down progression of the lo-
calized chorioretinal degeneration. However, partially due to
substantial difficulty in maintaining an arginine-restricted diet,
this hypothesis has been difficult to prove. Through use of the
mouse model, it is now clear that arginine restriction does in-
deed slow down disease progression. Ongoing studies are now
exploring the possible combined use of dietary restriction and
gene therapy approaches.
Bernhard H. F. Weber summarized recent studies on the
pathogenesis of Sorsby’s fundus dystrophy (SFD). SFD is an
autosomal dominantly inherited macular disorder with late
onset usually in the third or fourth decade of life. Abnormal
deposits of confluent lipid containing material in the inner
portion of Bruch’s membrane have been recognized as an early
manifestation of the disease [42]. Later in life, sudden loss of
central vision may occur either due to choroidal
neovascularization with subretinal hemorrhage and the devel-
opment of a disciform scar or, in the minority of patients, due
to atrophic changes.
Choroidal neovascularization is also a hallmark of the exu-
dative form of age-related macular degeneration (AMD). Simi-
lar to SFD, it is characterized by a submacular ingrowth of
choroidal vessels through a damaged Bruch’s membrane.
Therefore, a greater understanding of the primary causes of
the complex AMD may be gained by elucidating the molecu-
lar pathology of SFD.
Following the rationale of the positional candidate ap-
proach, mutations in the gene encoding the tissue inhibitor of
metalloproteinases-3 (TIMP3) were shown to be associated
with the SFD phenotype [43]. TIMP3 represents one member
of a growing family of distinct inhibitors of matrix
metalloproteinases (MMPs). Together or in concert with other
enzymes the MMPs can degrade most components of the ex-
tracellular matrix (ECM). Several studies have shown that
TIMP3 indeed is an extracellular matrix component of Bruch’s
membrane thus suggesting a direct role of mutant TIMP3 in
Bruch’s membrane associated pathology such as the forma-
tion of extracellular deposits as well as the ingrowth of chor-
oidal vessels [44,45].
To date, all mutations identified in SFD result in a substi-
tution of an amino acid by cysteine at the C-terminus of the
188 amino acid TIMP3 glycoprotein. The tertiary structure of
the normal protein is thought to be conferred by 12 conserved
cystein residues which form intramolecular disulfide bonds
along the entire polypeptide. The introduction of an additional
cysteine thiol-group should be expected to result in a TIMP3
protein with altered or impaired functional properties. To fur-
ther understand the molecular mechanisms underlying the spe-
cific mutations in SFD, a knock-in Ser156Cys as well as a
Ser156Met knock-in mutation were generated via a gene tar-
geting approach. The Ser to Cys alteration at amino acid resi-
due 156 was found to be associated with an unusual early on-
set of SFD [46,47]. In contrast, the Ser156Met mutation is not
known to cause a phenotype in human but may be crucial in
gaining additional insight into the basic mechanism underly-
ing the cysteine mutations. The mutated ES cells were injected
into C57Bl/6 blastocysts and chimeric mice were obtained from
all injected ES cells. So far, germ line transmission of the
Ser156Cys mutation has been achieved. Preliminary analysis
of the retinas of two month old mice reveal overall normal
morphology with a suggestion of thickening of Bruch’s mem-
brane and possible RPE mottling. No evidence of
neovascularization has been observed. Ongoing studies will
more fully define the phenotype of these mutant mice.
Over the next few years, one can be confident that an
increasing number of genes that when mutated can cause pho-
toreceptor loss will be identified. One can also be confident
that the combined use of biochemical, cell biological, and
transgenic and knock-out studies will provide important in-
formation about the functions of these genes, and about the
mechanisms by which alteration of the function can lead to
retinal disease. Hopefully, this new information will also pro-
vide insights about the etiology and pathogenesis of AMD.
However, along with this hope, one must also keep in mind
some of the questions raised by these studies of “other retinal
degenerations,” and the limitations of some of the methods
that have been used to study them. Among these questions
are: How can such similar phenotypes be caused by mutations
in such different genes? And how can mutations in the same
gene cause such different ocular phenotypes? What is the role
of modifier genes and the environment? Why is it so difficult
for retinal disease to define reliable genotype-phenotype cor-
relations? Since the mouse does not contain a macula, will it
be possible to develop a mouse transgenic or knock-out (knock-
in) model of AMD?
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The comments discussed are based on the following pre-
sentations made at the “Pathogenesis and Treatment of Age-
Related Macular Degeneration: Current Knowledge and Leads
for Future Research” symposium: Identification and charac-
terization of ABCR/RIM, a retina-specific abc transporter (by
Jeremy Nathans), The role of mutations in ABCR in macular
degenerative disorders (by Michael Dean), Inferring pathoge-
nicity—What can rare diseases and isolated populations teach
us about our search for amd genes? (by Edwin M. Stone),
Role of photoreceptor membrane proteins in retinitis
pigmentosa and macular degeneration (by Bob Molday), Tran-
scription factors can cause photoreceptor degeneration too:
the story of CRX (by Donald J. Zack), RPE65 gene mutations
and the retina: human disease and its knockout mouse model
(by T. Michael Redmond), LCA caused by a recessive CRX
mutation (by Anand Swaroop), Molecular studies of gyrate
atrophy (by David Valle) and New insights into Sorsby’s fun-
dus dystrophy: construction and analysis of knock-in mice (by
Bernhard H. F. Weber).
REFERENCES
1. Gorin MB, Breitner JCS, De Jong PTVM, Hageman GS, Klaver
CCW, Kuehn MH, Seddon JM. The Genetics of Age-related
Macular Degeneration. Mol Vis 1999; 5:27.
2. Stone EM, Fingert JH, Alward WLM, Nguyen TD, Polansky JR,
Sunden SLF, Nishimura D, Clark AF, Nystuen A, Nichols BE,
Mackey DA, Ritch R, Kalenak JW, Craven ER, Sheffield VC.
Identification of a gene that causes primary open angle glau-
coma. Science 1997; 275:668-70.
3. Allikmets R, Singh N, Sun H, et al. A photoreceptor cell-specific
ATP-binding transporter gene (ABCR) is mutated in recessive
Stargardt macular dystrophy. Nat Genet 1997; 15:236-46.
4. Illing M, Molday LL, Molday RS. The 220-kDa rim protein of
retinal rod outer segments is a member of the ABC transporter
superfamily. J Biol Chem 1997; 272:10303-10.
5. Sun H, Nathans J. Stargardt’s ABCR is localized to the disc mem-
brane of retinal rod outer segments. Nat Genet 1997; 17:15-6.
6. Sun H, Molday RS, Nathans J. Retinal stimulates ATP hydrolysis
by purified and reconstituted ABCR, the photoreceptor-specific
ATP-binding cassette responsible for Stargardt disease. J Biol
Chem 1999; 274:8269-81.
7. Martinez-Mir A, Paloma E, Allikmets R, Ayuso C, del Rio T, Dean
M, Vilageliu L, Gonzalez-Duarte R, Balcells S. Retinitis
pigmentosa caused by a homozygous mutation in the Stargardt
disease gene ABCR. Nat Genet 1998; 18:11-2.
8. Cremers FP, van de Pol DJ, van Driel M, den Hollander AI, van
Haren FJ, Knoers NV, Tijmes N, Bergen AA, Rohrschneider K,
Blankenagel A, Pinckers AJ, Deutman AF, Hoyng CB. Autoso-
mal recessive retinitis pigmentosa and cone-rod dystrophy
caused by splice site mutations in the Stargardt’s disease gene
ABCR. Hum Mol Genet 1998; 7:355-62.
9. Rozet JM, Gerber S, Souied E, Perrault I, Chatelin S, Ghazi I,
Leowski C, Dufier JL, Munnich A, Kaplan J. Spectrum of ABCR
gene mutations in autosomal recessive macular dystrophies. Eur
J Hum Genet 1998; 6:291-5.
10. Allikmets R, Shroyer NF, Singh N, Seddon JM, Lewis RA,
Bernstein PS, Peiffer A, Zabriskie NA, Li Y, Hutchinson A, Dean
M, Lupski JR, Leppert M. Mutation of the Stargardt disease
gene (ABCR) in age-related macular degeneration. Science
1997; 277:1805-7.
11. Dryja TP, Briggs CE, Berson EL, Rosenfeld PJ, Abitbol M, Klaver
CCW, Assink JJM, Bergen AAB, van Duijn CM, Dean M,
Allikmets R, Shroyer NF, Lupski JR, Lewis RA, Mark Leppert
M, Bernstein PS, Seddon JM. ABCR Gene and Age-Related
Macular Degeneration. Science Online [Online Supplement]
1998 February 20; 279:1107a <http://www.sciencemag.org/cgi/
content/full/279/5354/1107a>.
12. Stone EM, Webster AR, Vandenburgh K, Streb LM, Hockey RR,
Lotery AJ, Sheffield VC. Allelic variation in ABCR associated
with Stargardt disease but not age-related macular degenera-
tion. Nat Genet 1998; 20:328-9.
13. Nasonkin I, Illing M, Koehler MR, Schmid M, Molday RS, We-
ber BH. Mapping of the rod photoreceptor ABC transporter
(ABCR) to 1p21-p22.1 and identification of novel mutations in
Stargardt’s disease. Hum Genet 1998; 102:21-6.
14. Kajiwara K, Berson EL, Dryja TP. Digenic retinitis pigmentosa
due to mutations at the unlinked peripherin/RDS and ROM1
loci. Science 1994; 264:1604-8.
15. Goldberg AF, Molday RS. Defective subunit assembly underlies
a digenic form of retinitis pigmentosa linked to mutations in
peripherin/rds and rom-1. Proc Natl Acad Sci U S A 1996;
93:13726-30.
16. Goldberg AF, Moritz OL, Molday RS. Heterologous expression
of photoreceptor peripherin/rds and Rom-1 in COS-1 cells: as-
sembly, interactions, and localization of multisubunit complexes.
Biochemistry 1995; 34:14213-9.
17. Goldberg AF, Molday RS. Subunit composition of the peripherin/
rds-rom-1 disk rim complex from rod photoreceptors: hydrody-
namic evidence for a tetrameric quaternary structure. Biochem-
istry 1996; 35:6144-9.
18. Goldberg AF, Loewen CJ, Molday RS. Cysteine residues of pho-
toreceptor peripherin/rds: role in subunit assembly and autoso-
mal dominant retinitis pigmentosa. Biochemistry 1998; 37:680-
5.
19. Chen S, Wang QL, Nie Z, Sun H, Lennon G, Copeland NG, Gil-
bert DJ, Jenkins NA, Zack DJ. Crx, a novel Otx-like paired-
homeodomain protein, binds to and transactivates photorecep-
tor cell-specific genes. Neuron 1997; 19:1017-30.
20. Freund CL, Gregory-Evans CY, Furukawa T, Papaioannou M,
Looser J, Ploder L, Bellingham J, Ng D, Herbrick JA, Duncan
A, Scherer SW, Tsui LC, Loutradis-Anagnostou A, Jacobson
SG, Cepko CL, Bhattacharya SS, McInnes RR. Cone-rod dys-
trophy due to mutations in a novel photoreceptor-specific
homeobox gene (CRX) essential for maintenance of the photo-
receptor. Cell 1997; 91:543-53.
21. Furukawa T, Morrow EM, Cepko CL. Crx, a novel otx-like
homeobox gene, shows photoreceptor-specific expression and
regulates photoreceptor differentiation. Cell 1997; 91:531-41.
22. Li X, Chen S, Wang Q, Zack DJ, Snyder SH, Borjigin J. A pineal
regulatory element (PIRE) mediates transactivation by the pi-
neal/retina-specific transcription factor CRX. Proc Natl Acad
Sci U S A 1998; 95:1876-81.
23. Swaroop A, Xu JZ, Pawar H, Jackson A, Skolnick C, Agarwal N.
A conserved retina-specific gene encodes a basic motif/leucine
zipper domain. Proc Natl Acad Sci U S A 1992; 89:266-70.
24. Swain PK, Chen S, Wang QL, Affatigato LM, Coats CL, Brady
KD, Fishman GA, Jacobson SG, Swaroop A, Stone E, Sieving
PA, Zack DJ. Mutations in the cone-rod homeobox gene are
associated with the cone-rod dystrophy photoreceptor degen-
eration. Neuron 1997; 19:1329-36.
25. Sohocki MM, Sullivan LS, Mintz-Hittner HA, Birch D,
Heckenlively JR, Freund CL, McInnes RR, Daiger SP. A range
of clinical phenotypes associated with mutations in CRX, a pho-
toreceptor transcription-factor gene. Am J Hum Genet 1998;
63:1307-15.
© Molecular VisionMolecular Vision 1999; 5:30 <http://www.molvis.org/molvis/v5/p30>
26. Freund CL, Wang QL, Chen S, Muskat BL, Wiles CD, Sheffield
VC, Jacobson SG, McInnes RR, Zack DJ, Stone EM. De novo
mutations in the CRX homeobox gene associated with Leber
congenital amaurosis. Nat Genet 1998; 18:311-2.
27. Swaroop A, Wang QL, Wu W, Cook J, Coats C, Xu S, Chen S,
Zack DJ, Sieving PA. Leber congenital amaurosis caused by a
homozygous mutation (R90W) in the homeodomain of the reti-
nal transcription factor CRX: direct evidence for the involve-
ment of CRX in the development of photoreceptor function.
Hum Mol Genet 1999; 8:299-305.
28. Bessant DA, Payne AM, Mitton KP, Wang QL, Swain PK, Plant
C, Bird AC, Zack DJ, Swaroop A, Bhattacharya SS. A mutation
in NRL is associated with autosomal dominant retinitis
pigmentosa. Nat Genet 1999; 21:355-6.
29. Hamel CP, Tsilou E, Pfeffer BA, Hooks JJ, Detrick B, Redmond
TM. Molecular cloning and expression of RPE65, a novel reti-
nal pigment epithelium-specific microsomal protein that is post-
transcriptionally regulated in vitro. J Biol Chem 1993;
268:15751-7.
30. Nicoletti A, Wong DJ, Kawase K, Gibson LH, Yang-Feng TL,
Richards JE, Thompson DA. Molecular characterization of the
human gene encoding an abundant 61 kDa protein specific to
the retinal pigment epithelium. Hum Mol Genet 1995; 4:641-9.
31. Gu SM, Thompson DA, Srikumari CR, Lorenz B, Finckh U,
Nicoletti A, Murthy KR, Rathmann M, Kumaramanickavel G,
Denton MJ, Gal A. Mutations in RPE65 cause autosomal reces-
sive childhood-onset severe retinal dystrophy. Nat Genet 1997;
17:194-7.
32. Marlhens F, Bareil C, Griffoin JM, Zrenner E, Amalric P, Eliaou
C, Liu SY, Harris E, Redmond TM, Arnaud B, Claustres M,
Hamel CP. Mutations in RPE65 cause Leber’s congenital amau-
rosis. Nat Genet 1997; 17:139-41.
33. Hamel CP, Jenkins NA, Gilbert DJ, Copeland NG, Redmond TM.
The gene for the retinal pigment epithelium-specific protein
RPE65 is localized to human 1p31 and mouse 3. Genomics 1994;
20:509-12.
34. Redmond TM, Yu S, Lee E, Bok D, Hamasaki D, Chen N, Goletz
P, Ma JX, Crouch RK, Pfeifer K. Rpe65 is necessary for pro-
duction of 11-cis-vitamin A in the retinal visual cycle. Nat Genet
1998; 20:344-51.
35. Maw MA, Kennedy B, Knight A, Bridges R, Roth KE, Mani EJ,
Mukkadan JK, Nancarrow D, Crabb JW, Denton MJ. Mutation
of the gene encoding cellular retinaldehyde-binding protein in
autosomal recessive retinitis pigmentosa. Nat Genet 1997;
17:198-200.
36. Petrukhin K, Koisti MJ, Bakall B, Li W, Xie G, Marknell T,
Sandgren O, Forsman K, Holmgren G, Andreasson S, Vujic M,
Bergen AA, McGarty-Dugan V, Figueroa D, Austin CP, Metzker
ML, Caskey CT, Wadelius C. Identification of the gene respon-
sible for Best macular dystrophy. Nat Genet 1998; 19:241-7.
37. Mitchell GA, Brody LC, Looney J, Steel G, Suchanek M, Dowling
C, Der Kaloustian V, Kaiser-Kupfer M, Valle D. An initiator
codon mutation in ornithine-delta-aminotransferase causing
gyrate atrophy of the choroid and retina. J Clin Invest 1988;
81:630-3.
38. Brody LC, Mitchell GA, Obie C, Michaud J, Steel G, Fontaine
G, Robert MF, Sipila I, Kaiser-Kupfer M, Valle D. Ornithine
delta-aminotransferase mutations in gyrate atrophy. Allelic het-
erogeneity and functional consequences. J Biol Chem 1992;
267:3302-7.
39. Mashima Y, Shiono T, Inana G. Rapid and efficient molecular
analysis of gyrate atrophy using denaturing gradient gel elec-
trophoresis. Invest Ophthalmol Vis Sci 1994; 35:1065-70.
40. Wang T, Lawler AM, Steel G, Sipila I, Milam AH, Valle D. Mice
lacking ornithine-delta-aminotransferase have paradoxical neo-
natal hypoornithinaemia and retinal degeneration. Nat Genet
1995; 11:185-90.
41. Wang T, Milam AH, Steel G, Valle D. A mouse model of gyrate
atrophy of the choroid and retina. Early retinal pigment epithe-
lium damage and progressive retinal degeneration. J Clin In-
vest 1996; 97:2753-62.
42. Capon MR, Marshall J, Krafft JI, Alexander RA, Hiscott PS,
Bird AC. Sorsby’s fundus dystrophy. A light and electron mi-
croscopic study. Ophthalmology 1989; 96:1769-77.
43. Weber BH, Vogt G, Pruett RC, Stohr H, Felbor U. Mutations in
the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients
with Sorsby’s fundus dystrophy. Nat Genet 1994; 8:352-6.
44. Vranka JA, Johnson E, Zhu X, Shepardson A, Alexander JP, Bra-
dley JM, Wirtz MK, Weleber RG, Klein ML, Acott TS. Discrete
expression and distribution pattern of TIMP-3 in the human
retina and choroid. Curr Eye Res 1997; 16:102-10.
45. Fariss RN, Apte SS, Olsen BR, Iwata K, Milam AH. Tissue in-
hibitor of metalloproteinases-3 is a component of Bruch’s mem-
brane of the eye. Am J Pathol 1997; 150:323-8.
46. Felbor U, Stohr H, Amann T, Schonherr U, Apfelstedt-Sylla E,
Weber BH. A second independent Tyr168Cys mutation in the
tissue inhibitor of metalloproteinases-3 (TIMP3) in Sorsby’s
fundus dystrophy. J Med Genet 1996; 33:233-6.
47. Felbor U, Stohr H, Amann T, Schonherr U, Weber BH. A novel
Ser156Cys mutation in the tissue inhibitor of metalloproteinases-
3 (TIMP3) in Sorsby’s fundus dystrophy with unusual clinical
features. Hum Mol Genet 1995; 4:2415-6.
© Molecular VisionMolecular Vision 1999; 5:30 <http://www.molvis.org/molvis/v5/p30>
